CAMBRIDGE, Mass.--(BUSINESS WIRE)--Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited (TSE:4502) today announced that 101 abstracts featuring the Company’s oncology molecules have been accepted at the annual meeting of the American Society of Clinical Oncology (ASCO) being held in Chicago, Illinois, June 1-5, 2012. These data include oral presentations on clinical investigations of MLN9708, the first oral proteasome inhibitor being studied in patients with multiple myeloma. Also featured are poster discussions on clinical investigations of TAK-700, a selective 17,20 lyase inhibitor, dosed without steroids in patients with non-metastatic prostate cancer and trials of MLN8237, a selective Aurora A kinase inhibitor, in ovarian and breast cancer patients.
